Geriatric Cardiology in Dogs - Part 1: Classification and Treatment of Heart Failure in Geriatrics

Kürşad TURGUT 1 Havva SÜLEYMANOĞLU 1 Merve ERTAN 1 Mehmet Ege İNCE 1

1 Department of Internal Medicine, Faculty of Veterinary Medicine, Near East University, Near East Boulevard, 99138, Nicosia - NORTHERN CYPRUS

Article Code: KVFD-2017-18580 Received: 10.08.2017 Accepted: 24.10.2017 Published Online: 26.10.2017

Abstract

The purpose of this article is to give current information on the effect of aging on heart, classification of heart failure (HF) in geriatric dogs and therapeutic advances and challenges. The aging process results in a host of physiological and biological changes that lead to progressive HF. Nearly any cardiovascular disease (CVD) can lead to HF. HF in geriatric dogs is broadly classified into: Diastolic heart failure is defined as HF with preserved ejection fraction (HF/PEF), systolic heart failure is also known as HF with low ejection fraction (HF/low-EF). Importantly, HF/PEF accounts for approximately 50% of all HF patients and its prevalence is higher in the elderly. In humans, mortality and morbidity benefits for HF/low-EF have been reported with angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), β-blockers and aldosterone antagonists, and the hydralazine–nitrate combination in patients intolerant to ACE inhibitors or nitrates. Therapies for symptom control and morbidity benefit include diuretics and digoxin. The most common and suggested therapy for dogs with HF by ACVIM panelists is furosemide, ACE-I and pimobendan. Pharmacological therapy is limited for HF/PEF as the results of small trials have been inconclusive. To date, clinical trials in HF/PEF patients have not shown mortality benefit so that management is focused on symptom relief and treatment of the underlying cause.

Keywords: Geriatric Cardiology, Classification, Treatment, Heart Failure, Dog

INTRODUCTION

Why geriatric cardiology is important?
Is the term geriatric cardiology redundant?

Technically, geriatric cardiology refers to cardiovascular care of dogs 9 years of age or older (giant breed >7.5 years) [1]. It is the practice of cardiovascular (CV) medicine that is adapted to the needs of older dogs. To some degree, all cardiologists know this, recognize this, and in varying capacities, practice this.

Not surprisingly, a recent survey in Near East University, Veterinary Hospital found that almost 50% of patients who

İletişim (Correspondence)
+90 533 8594430
kturgut@selcuk.edu.tr

Köpeklerde Geriatrik Kardiyoloji - Bölüm 1: Geriatriklerde Kalp Yetmezliğinin Klasifikasyonu ve Tedavisi

Özet


Anahtar sözcükler: Geriatrik kardiyoloji, Klasifikasyon, Tedavi, Kalp yetmezliği, Köpek
Geriatric Cardiology in Dogs - ...

visited Hospital over the last year would be considered geriatric on the basis of age alone.

But, is there reason to believe that cardiovascular management of these older dogs differs from that of younger cardiovascular patients?

A clue comes from the mission statement of the geriatric cardiology member section of the American College of Cardiology (ACC), which states that the practice of geriatric cardiology should consider “all matters related to cardiovascular care-giving in relation to aging” [2].

In older dogs, multiple medical problems (hypertension, diabetes, hyperlipidemia, frailty, cognitive dysfunction (CD) lead to polypharmacy. Compounding these burdens is that older patients have not only considerable clinical needs, but psychological and social needs too [3-5].

In humans, polypharmacy, defined as the concurrent use of 5 or more medications, occurs in up to 40% of older patients. Absorption, bioavailability, and volume of distribution of pharmacologic agents change dramatically with age, significantly increasing the risk of drug interactions, particularly in patients with polypharmacy [6]. Importantly, the risk of adverse drug effects is about 50% in patients on 4 chronic medications and approaches 100% in those taking more than 7. Moreover, almost one-half of hospitalizations related to adverse drug events are attributable to cardiovascular medications (particularly diuretics, warfarin, beta-blockers, and angiotensin-converting enzyme inhibitors) [7]. The challenge is to prioritize treatments, minimize dangerous interactions, and optimize quality of life [8].

Recommendations require thoughtful individualization, based on integrating patient-centered priorities with respect to each patient's aging experience. This article focuses on the effect of ageing on heart, classification of HF in geriatric dogs and therapeutic advances and challenges.

EFFECTS OF AGING ON THE CARDIOVASCULAR SYSTEM

An accurate biomarker of aging is lacking. Pathophysiologic hallmarks of cardiovascular aging are summarized in Table 1 [8-10].

THE IMPORTANT CARDIOVASCULAR DISEASES IN GERIATRIC DOGS

Most dogs born with congenital heart disease died when they were young and did not reach old age or had the defect corrected surgically (eg, patent ductus arteriosus), and the defect is thus of no concern in old age.

The aging process results in a host of physiological and biological changes that lead to progressive HF (Table 1). Nearly any cardiovascular disease (CVD) can lead to HF. Common CVDs causing HF in geriatric dogs are given in Table 2 [1,4,5,11,12].

HEART FAILURE

Heart failure (HF) is a major healthcare burden in dogs and a particularly important problem in the elderly dogs. This is the most common disorder in small animals' cardiorespiratory clinics, commonly the end-stage in a CVD continuum (Fig. 1). It is characterized with progressive decrease in cardiac output and ventricular filling [9,13].

Definition of HF: Definitions of HF in dogs and humans is based on a clinical syndrome that emphasizes symptoms and signs [5,11]. Briefly, the HF syndrome consists of a triad of;

Typical symptoms; exercise intolerance, weakness, weight loss, chronic cough, peripheral edema, orthopnoea, syncope, inappetence.

Typical signs; tachyarythmia, tachypnea, pulmonary rales, ascites, pleural effusion, raised jugular venous pressure, hepatomegaly.

Objective evidence of structural and functional abnormality; cardiomegaly, cardiac murmurs, abnormal echocardiogram or raised atrial natriuretic peptide marker level.

Pathophysiology: Most HF patients have myocardial dysfunction. Common causes include muscle damage or loss from mitral regurgitation, hypertensive (pulmonary/systemic) cardiomyopathy, atherosclerosis, diabetic cardiomyopathy, increased vascular resistance and afterload from hypertension, and increased heart rate from tachyarrhythmias such as atrial fibrillation [4,5,11,14].

Early cardiocirculatory, hemodynamic and cardio-renal HF models emphasized decreased pump function, cardiac output and renal blood flow, and increased peripheral vasoconstriction and provided the rationale for using diuretics, inotropes and vasodilators [10].

Subsequently, the neurohumoral model emphasized the development and progression of asymptomatic to symptomatic HF. In this construct, injury leads to activation of the adrenergic nervous system (ANS), the reninangiotensin-aldosterone system (RAAS) and cytokine systems that preserve LV function in the short term, and to secondary damage with maladaptive LV remodeling and worsening HF in the long term. After that, LV remodeling is severe and impaired healing can further aggravate remodeling in the elderly [15,16].

Whereas activation of the ANS decreases during the progression of HF resulting in decreased norepinephrine (owing to an exhaustion phenomenon) and reuptake, RAAS activation persists. The neurohumoral model provided
rationale for using ACE inhibitors, ARBs, aldosterone antagonists and β-blockers in HF \[15\].

While most angiotensin II, the major effector molecule of the RAAS, is formed via the ACE-dependent pathway, angiotensin II can also be produced through renin- and ACE-independent pathways. Angiotensin II acts through the angiotensin II type 1 (AT1) and angiotensin II type 2 (AT2) receptors. The predominant subtype is AT1 in the vasculature and AT2 in the myocardium, with localization of AT1 in nerves and AT2 in fibroblasts and the interstitium. AT1 activation leads to vasoconstriction, cell growth, aldosterone secretion and catecholamine release, whereas AT2 activation leads to vasodilation, the inhibition of cell growth, natriuresis and bradykinin release. The ratio of AT1 to AT2 receptors decreases in HF. Sustained expression of angiotensin II leads to cardiac and renal fibrosis (partly through increased aldosterone), cardiac hypertrophy, and maladaptive cardiac and vascular remodeling. Aldosterone also leads to the inhibition of norepinephrine re-uptake and worsening HF \[4,5,15,17\].

Classification of HF: The new ACVIM (American College of Veterinary Internal Medicine) classification of cardiac disease that was adapted from the American College of Cardiology and uses an A-through-D categorization scheme (stage A with risk of HF but no structural changes or symptoms; stage B with structural changes but no signs or symptoms; stage C with structural changes and prior or current symptoms; stage D with severe refractory HF requiring specialized interventions \[5,18,19\].

### Table 1. Pathophysiological changes and pathophysiologic hallmarks during aging

- Dysregulation of repair mechanisms: decreased endothelial nitric oxide production and increased endothelial apoptosis, superoxide production and advanced glycation end product
- Fibrotic cardiac remodeling: diastolic and systolic dysfunction
- Remodeling of the vascular wall: arterial stiffening
- Increased collagen, decreased elastin and calcification: atrial fibrillation, bradyarrhythmias
- Increase in fibrinogen, coagulation factors, platelet activity, plasminogen activator inhibitor-1, prothrombotic cytokines: atherosclerosis
- Enhanced adherence of mononuclear cells to the endothelial surface, promoting an inflammatory microvascular environment: tromboembolizm
- Abnormal adrenergic responses: blunted β1-adrenergic myocardial contractility and β2-adrenergic vasodilatation
- Limited ATP production: less contraction or relaxation in response to stress

### Table 2. The most common diseases causing HF in geriatric dogs

- Mitral regurgitation; valvular diseases, DCM
- Hypertensive (pulmonary/systemic) cardiomyopathy
- Atherosclerosis
- Diabetic cardiomyopathy (hyperlipidemia, Type 2 diabetes)

### References

1. [Turgut, Süleymanoğlu, Ertan, İnce](#)
2. [Rationale for using ACE inhibitors, ARBs, aldosterone antagonists and β-blockers in HF](#)
3. [While most angiotensin II, the major effector molecule of the RAAS, is formed via the ACE-dependent pathway](#)
4. [Angiotensin II can also be produced through renin- and ACE-independent pathways](#)
5. [Angiotensin II acts through the angiotensin II type 1 (AT1) and angiotensin II type 2 (AT2) receptors](#)
6. [The predominant subtype is AT1 in the vasculature and AT2 in the myocardium](#)
7. [With localization of AT1 in nerves and AT2 in fibroblasts and the interstitium](#)
8. [AT1 activation leads to vasoconstriction, cell growth](#)
9. [Aldosterone secretion and catecholamine release](#)
10. [Whereas AT2 activation leads to vasodilation, the inhibition of cell growth](#)
11. [Natriuresis and bradykinin release](#)
12. [The ratio of AT1 to AT2 receptors decreases in HF](#)
13. [Sustained expression of angiotensin II leads to cardiac and renal fibrosis](#)
14. [Partly through increased aldosterone](#)
15. [Cardiac hypertrophy](#)
16. [Maladaptive cardiac and vascular remodeling](#)
17. [Aldosterone also leads to the inhibition of norepinephrine re-uptake](#)
18. [And worsening HF](#)
19. [Classification of HF: The new ACVIM (American College of Veterinary Internal Medicine) classification of cardiac disease that was adapted from the American College of Cardiology and uses an A-through-D categorization scheme](#)
20. [Stage A with risk of HF but no structural changes or symptoms](#)
21. [Stage B with structural changes but no signs or symptoms](#)
22. [Stage C with structural changes and prior or current symptoms](#)
23. [Stage D with severe refractory HF requiring specialized interventions](#)
Currently, HF in geriatric dogs is considered to be the result of structural and functional cardiac disorders that impair ventricular filling and ejection, and is broadly classified into:

- Diastolic heart failure (DHF), HF with preserved ejection fraction (HF/PEF).
- Systolic heart failure (SHF), HF with low ejection fraction (HF/low-EF).

Importantly, HF/PEF accounts for approximately 50% of all HF patients and its prevalence is higher in the elderly [20,21].

**Treatment of HF:** Although HF is primarily a disorder of the elderly, there is a lack of evidence-based data from randomized clinical trials (RCTs) of HF, specifically in elderly patients and geriatric dogs. More often drugs have to be chosen based on pathophysiological logic. Dose adjustments are necessary so as not to cause harm [4,5].

**Therapies for HF/low-EF:** In humans, mortality and morbidity benefits have been reported with angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), β-blockers and aldosterone antagonists, and the hydralazine–nitrate combination in patients intolerant to ACE inhibitors or nitrates. Therapies for symptom control and morbidity benefit include diuretics and digoxin [7,18].

The most common and suggested therapy for dogs with HF by ACVIM panelists is furosemide, ACE-I, pimobendan. For the following drugs, no consensus has been reached by ACVIM panelists at C1 stage of the disease. ACE-I (dose depends of the drug used) (Enalapril 0.5 mg/kg, 1-2x/d p.o.; Benazepril 0.25-0.5 mg/kg, 1-2x/d p.o.) can be given Class C2 and D dogs [5,18,22].

Although every attempt should be made to use target doses shown to produce mortality benefit in RCTs, it is advisable in elderly patients to start at a low dose and uptitrate to the tolerated dose. Similar precautions are needed in elderly HF patients [4,11]. Over 75% of patients still do not receive the optimal dose of ACE inhibitors. In elderly patients who cannot tolerate the target dose, a lower dose of an ACE inhibitor is still beneficial but a β-blocker should be introduced [11].

- **Angiotensin Receptor Blockers:** Most RCTs for ARBs used ACE inhibitors as comparator and patients received other background therapy such as β-blockers and/or diuretics. In the Valsartan Heart Failure Trial (Val-HeFT), overall mortality was similar in valsartan and placebo groups but combined morbidity and mortality was lower with valsartan [4,28]. In contrast to Val-HeFT, the candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM)-Added trial with candesartan on top of an ACE inhibitor and background therapy showed a reduction in the primary end point (hospitalization or death) [29]. In the CHARM-Alternative trial, use of candesartan in ACE inhibitor-intolerant patients reduced morbidity and mortality [30]. However, 7.7% of the patients developed angioedema.

Similar precautions as with ACE inhibitors should be observed with ARBs [11]. It is reasonable to add a β-blocker before the target dose of an ARB is reached in stable patients.

- **Pimobendan:** Pimobendan does increase contractility without increasing myocardial oxygen consumption. In addition, pimobendan exerts a peripheral vasodilatory effect by phosphodiesterase III inhibition, which may not only be important in the systemic but also in the pulmonary circulation. Furthermore, the vasodilation affects arteries as well as veins, therefore it is expected to reduce afterload and preload. Finally, it may have an anticytokine effect. The ACVIM panelists suggest also using pimobendan at 0.1-0.3 mg/kg q 12 h in dogs with HF [18,22]. It can be combined with many drugs, e.g. furosemide, ACE inhibitors, betablockers, digoxin and amiodpine [10].

**β-blockers.** The majority of RCTs added a β-blocker to background therapy that included ACE inhibitors. The addition of a β-blocker to an ACE inhibitor and a diuretic is recommended in clinically stable stage C patients with or without symptoms [11]. Compelling evidence of mortality benefits exists for bisoprolol, sustained-release metoprolol succinate and carvedilol. A meta-analysis of five RCTs with more than 12,000 patients, of whom 4617 (36.3%) were elderly, showed mortality benefits with those three
β-blockers [3,11,32]. β-blockers are therefore recommended in elderly patients with HF/low-EF.

In dogs with HF, β-blockers can be used in cases of atrial fibrillation to control the ventricular rate, or ventricular arrhythmias [18].

Mitochondria in hearts of aged patients seem to be unable to produce increased amounts of ATP to fuel contraction or relaxation in response to stress. The β-adrenergic blocking agents may improve exercise capacity dramatically, in human.

Which of these issues is applicable to the aging pet is unknown [18].

Initiation with the lowest tolerated dose and gradual escalation reduce the risk of hypotension and bradycardia. When hypotension and bradycardia are accompanied by evidence of hypoperfusion (i.e., cold extremities, or worsening of renal or hepatic function), the dose should be decreased or the drug withdrawn (Carvedilol, 0.05-0.4 mg/kg, 1-2×/d p.o.; Atenolol, 0.2-1.5 mg/kg, 1-2×/d p.o.) [4,5].

- Diuretics: Patients with a history or symptoms of HF and evidence of fluid retention should be treated with sodium restriction and diuretics such as loop diuretics (furosemide, torsemide and bumetanide), thiazides (metolazone and hydrochlorothiazide) or aldosterone antagonists (spironolactone and eplerenone). Loop diuretics increase sodium excretion (by 25% of filtered load) and free-water clearance unless renal function is severely impaired (creatinine clearance <10 mL/L). Thiazides increase fractional sodium excretion (by 5-10% of filtered load) and decrease free-water clearance unless renal function is moderately impaired (creatinine clearance <30 mL/L) [4,5,33-35].

The ACVIM panel suggested for C1 dogs, furosemide 1-4 mg/kg IV, IM or SC as bolus or 1 mg/kg, constant rate infusion (CRI), the latest being reserved for dogs not responding to a bolus injection. In some cases higher doses of furosemide such as 4-8 mg/kg can be given in severe pulmonary edema cases; the dose depends on the kidney status of the animal, the amount of water taken and age. Monitoring respiratory rate, ECG, urine output and drinking is essential [5,18,33].

Furosemide (1-2 mg/kg q12 h to 4-6 mg/kg q 8 h orally) can be given to Class C2 and D1, D2 dogs with careful monitoring of renal parameters; mild azotemia is unavoidable and well tolerated. Diuresis can be increased by higher dosage or increased frequency of application, also in refractory cases furosemide can be given by SQ injection by the owner instead of a tablet. In these cases, additional diuretics are added like hydrochlorothiazide (1-2 mg q 12-24 h), spironolactone (0.5-2 mg/kg q 24 h) or torsemide (0.1× dose of furosemide) [5,18,33].

Hydrochlorothiazide (2-4 mg/kg q 12 h) and torsemide (0.2 mg/kg q 12-24 h) instead of furosemide can be used in C2 dogs [5,18,33].

Patients on diuretics should be closely monitored. The dose should be individualized, especially in the elderly who are susceptible to orthostatic hypotension and renal dysfunction from over-diuresis. Too low a dose can lead to fluid retention, which in turn can blunt the response to ACE inhibitors and decrease tolerance of β-blockers. Too high a dose can lead hypovolemia, increased susceptibility to hypotension from ACE inhibitors, ARBs and/or other vasodilators, and renal insufficiency from ACE inhibitors or ARBs [4].

In the elderly, it is prudent to initiate therapy with a low dose and titrate upward based on the diuretic response and weight loss. Hypokalemia and hypomagnesemia should be promptly treated to prevent arrhythmias, especially if digoxin is being used. When a loop diuretic is used, an ACE inhibitor or ARB alone, or in combination with an aldosterone antagonist, may reduce the risk of electrolyte depletion [5,18,33].

- Aldosterone Antagonists: An important aspect of the RAAS is the AT1 receptor-mediated activation of aldosterone, which promotes sodium retention, loss of magnesium and potassium, sympathetic activation, parasympathetic inhibition, myocardial and vascular fibrosis, baroreceptor dysfunction, vascular damage and impaired arterial compliance. The rationale for using aldosterone antagonists is that angiotensin II stimulates the release of aldosterone, thereby activating the mineralocorticoid receptor, and the activation of this receptor persists despite the use of ACE inhibitors, ARBs and β-blockers [5,16,37].

While aldosterone antagonists are typically used for their mortality benefits, long-term studies of other diuretics on morbidity and mortality in HF are lacking [36,37]. In dogs with HF, spironolactone is used for its diuretic, potassium-sparing and presumably anti-fibrotic properties [5,16,37].

Based on evidence from two RCTs [34], the addition of an aldosterone antagonist is considered reasonable in patients with moderate-to-severe HF and reduced EF, provided renal function (serum creatinine ≤2.5 mg/dL in men and ≤2.0 mg/dL in women) and serum potassium ≤5.0 mEq/L can be carefully monitored [11].

The Randomized Aldactone Evaluation Study for Congestive Heart Failure (RALES), which assessed spironolactone on top of background therapy with ACE inhibitors, β-blockers, diuretics and digoxin in patients with moderate-to-severe HF (EF <35%), was prematurely terminated owing to an early finding of a 30% reduction in all-cause mortality but also reduced morbidity and hospitalization [34].

- Digoxin: The addition of digoxin is recommended if HF symptoms persist despite optimal treatment with an ACE inhibitor, β-blocker and/or a diuretic [11]. The Randomized
Assessment of Digoxin on Inhibitors of Angiotensin-
Converting Enzyme (RADIANCE) study reported worsening
after the withdrawal of digoxin in HF patients who were in
sinus rhythm and stable on a regimen of digoxin, diuretics
and ACE inhibitors [48].

In dogs with HF, digoxin (0.22 mg/m²) can be used for rate
control [18]. Since digoxin has a narrow therapeutic index
and is excreted by the kidneys and the elderly are at risk of
renal dysfunction and/or lean body mass loss, a low initial
dose of 0.125 mg daily or every other day should be used
in patients aged over 70 years [11]. While the serum digoxin
level does not seem to correlate with clinical benefits,
a serum digoxin level over 1 ng/mL is associated with
increased mortality, in humans [39]. A level less than 1.2
ng/mL might therefore be safer for dogs [3].

- Vasodilators: Based on three RCTs, the addition of a
combination of isosorbide dinitrate and hydralazine is
considered reasonable if the symptoms persist despite
ACE inhibitor and β-blocker therapy, or if patients are
intolerant to ACE inhibitors or ARBs [11]. Val-HeFT I reported
that the addition of isosorbide dinitrate and hydralazine
can be favourable in male patients with mild-to-severe
HF (EF <45%) receiving digoxin and diuretics (isosorbide
dinitrate ½-1 hub, rubben on hairless skin; Hydralazine
0.5-3 mg/kg orally q 12 h for dogs) [4,40].

Amlodipine (0.15-0.25 mg/kg SID), needs to be titrated and
monitor blood pressure) can be used in C2 and D1 dogs,
especially in cases with high blood pressure because of
renal failure [5,46].

Medical Therapy of HF/PEF: Heart failure/PEF increases
with age, is very common in the elderly [21]. It considers
HF/PEF as a triad of [41]: (1) signs and symptoms of HF, (2)
normal or mildly abnormal LV systolic function (LV EF
>50% or LV end-diastolic volume index <97 mL/m²), and (3) evidence of LV diastolic dysfunction (echocardiographic/Doppler E/E’ >15, E’< 8 cm/sn or elevated NTproBNP concentration >450 pmol/L with abnormal echocardiographic/ Doppler parameters) [5,42].

In contrast to HF/low-EF, patients with HF/PEF are more
likely to be elderly, and hypertensive, and less likely to
have previous therapy with ACE inhibitors and ARBs [40].

Mortality is similar to that with HF/low-EF. While survival
over time has improved for HF/low-EF, it has remained
unchanged for HF/PEF. Major causes of HF/PEF in the
elderly include LV hypertrophy, hypertrophic cardio-
myopathy, aortic stenosis with normal EF, ischemic heart
disease, restrictive cardiomyopathy with idiopathic causes
or infiltrative cardiomyopathy [44]. In humans, it is believed
that systolic dysfunction is a consequence of diastolic
dysfunction because of decreased preload [4].

The nonpharmacological strategy is similar to that for
patients with HF/low-EF (i.e., daily monitoring of weight,
attention to diet and lifestyle, and close medical follow-
up) together with aggressive control of hypertension,
tachycardia and other precipitating causes of de-
compensation. Emerging evidence suggests that exercise
training improves outcome (i.e., improves quality of life,
increases longevity and decreases symptoms) [40].

Pharmacological therapy is limited as the results of small
trials have been inconclusive. To date, clinical trials in HF/
PEF patients have not shown mortality benefit so that
management is focused on symptom relief and treatment
of the underlying cause. Beyond, the established beneficial
effects of ACE inhibitors in patients with hypertension
that may be due, at least in part, to attenuation of cardiac
fibrosis or other anti-fibrotic strategies (such as AGE
breakers) may exert beneficial actions in high-risk elderly
patients with diastolic heart failure [9]. In the Perindopril in
Elderly People with Chronic Heart Failure (PEF-CHF) trial,
the ACE inhibitor perindopril in patients aged over 70
years (mean: 76 years of age) and HF-PEF did not reduce
the primary end point but the event rates were lower than anticipated [26]. However, there was a trend towards
reduced HF hospitalization at 1 year.

In the CHARM-Preserved trial in patients with mild-
to-moderate HF and LV EF more than 40%, the ARB
candesartan on top of standard therapy had no mortality
benefit; 22% of patients in the candesartan group and
24% in the placebo group reached the primary end point
(cardiovascular death or HF hospitalization) [45].

In the irbesartan in Patients with Heart Failure and
Preserved Ejection Fraction Study (I-PRESERVE), the ARB
irbesartan in 4128 patients aged 60 years or over (mean:
72 years of age) showed no benefit [46].

In a substudy of the Digitalis Investigation Group (DIG)
trial, digoxin did not change the primary end point of HF
hospitalization or cardiovascular mortality [47].

In summary, specific medical therapy for HF/PEF is lacking.
Current recommendations for the treatment of HF/PEF include
[4,11]: (a) control of systolic and diastolic hyper-
tension, (b) control of ventricular rate in patients with
atrial fibrillation, (c) control of pulmonary congestion and
peripheral edema with diuretics, (d) treatment of coronary
artery disease and demonstrable myocardial ischemia with
coronary revascularization, (e) restoration and maintenance
of sinus rhythm in patients with atrial fibrillation, (f) use
of digoxin in selected patients.

Other HF Treatments

- Supraventricular Arrhythmias: Both patients with HF/
PEF and HF/low-EF develop atrial fibrillation and other
supraventricular arrhythmias [48]. Deleterious effects of
supraventricular tachyarrhythmias are due to: (1) loss of
atrial contribution to ventricular filling, (2) increased
myocardial oxygen demands and decreased perfusion, (3)
impaired contraction and relaxation, (4) stasis of blood in the atria leading to thrombus formation and embolism, (5) the development of cardiomyopathy from sustained tachycardia [11].

Atrial fibrillation is the most common treatable supraventricular or atrial arrhythmia. It leads to decreased exercise capacity and aggravates long-term prognosis. Atrial fibrillation begets atrial fibrillation, which begets HF. It is also more common in the elderly [49].

Two important aspects of therapy in HF patients are rate and/or rhythm control and prevention of thromboembolism. The goal is to decrease the ventricular rate to less than 80-90 bpm at rest and to less than 110-130 bpm with moderate exercise [11].

Digoxin is more effective in slowing atrioventricular (AV) conduction at rest than during exercise. β-blockers are more effective than digoxin during exercise. The combination of digoxin and β-blockers may be more effective for rate control. When β-blockers fail to control HF or are contraindicated, amiodarone (10 mg/kg orally q 12 h for 7-14 days or 10-15 mg/kg orally q 24 h for 7-14 days, than 5-7.5 mg/kg orally q 24 h for dogs) can be used. If pharmacotherapy fails to control heart rate, AV-node ablation is indicated. R-wave synchronized cardioversion is recommended when rapid rate is unresponsive to therapy for patients with ischemia, hypotension angina or HF [48].

Anticoagulation should be maintained in all patients with atrial fibrillation regardless of whether sinus rhythm is restored owing to the high recurrence rate with associated embolic risk [3].

Ventricular Arrhythmias, Sudden Death: Both patients with HF/PEF and HF/low-EF can develop ventricular arrhythmias and sudden death. Sudden death can result from two main causes: (1) arrhythmias, usually ventricular tachyarrhythmias such as non-sustained or sustained ventricular tachycardia (VT) but less often bradycardia and pulseless supraventricular rhythms, especially in stage D HF, (2) ischemia with ACS and acute MI, electrolyte imbalance and vascular events, including pulmonary and systemic embolism [11].

In addition, HF/low-EF patients with dilative LV remodeling are prone to develop VT (non-sustained or sustained) and sudden death besides non-sudden death from pump failure [11].

Definitive therapy for myocardial ischemia or other reversible factors can prevent the recurrence of tachyarrhythmia such as polymorphic VT, non-sustained VT and ventricular fibrillation. Medical therapies that decrease disease progression such as Lidocain (2 mg/kg i.v. over 1-2 min (repeat in 2 mg/kg boluses up to 8 mg/kg in 10 min) or 0.8 mg/kg/min i.v. infusion (up to 8 mg/kg)), β-blockers [32,50] and aldosterone antagonists [36,37] can decrease sudden deaths in HF/low-EF patients.

In addition, the negative inotropic effects of antiarrhythmic drugs is a concern as they may aggravate HF and augment the risk of serious arrhythmias in HF/low-EF patients [5].

Importantly, in humans, implantable cardioverter-deﬁbrillator (ICD) devices that terminate sustained arrhythmias can further decrease sudden death in that group. ICDs are therefore recommended for all patients with life-threatening tachyarrhythmias and otherwise good prognosis [11].

Patients with stage D HF/low-EF often (in 33%) have a QRS duration of more than 0.12 s and LV dyssynchrony or delayed activation of the LV free wall. Ventricular dyssynchrony is associated with increased mortality in HF patients. Previously known as biventricular pacing, cardiac resynchronization therapy (CRT) re-coordinates ventricular beating by the insertion of atrial-synchronized biventricular pacing catheters, thereby eliminating dyssynchrony [51]. CRT can also reduce secondary mitral regurgitation.

Other Considerations: Hospitalized stage C/D HF patients are at increased risk for thromboembolic complications and should receive prophylactic anticoagulation with intravenous unfractionated heparin (Heparin sodium: 300-500 IU/kg i.v. (loading dose), then 100-300 IU/kg s.c. q 6-8 h) or low- molecular-weight heparin (Dalteparin: 100-150 IU/kg s.c. q8h) unless contraindicated. Warfarin is a reasonable in HF patients with antecedent embolic events or with paroxysmal or persistent atrial fibrillation [52].

Surgical Management of Refractory End-Stage HF (Stage D): Ventricular assist devices (VADs), cardiac transplantation, total artificial hearts, myocardial vascularization with coronary artery bypass grafting (CABG) and mitral valve repair or replacement are beneﬁcial in stage D patients with demonstrable myocardial viability, in human [43,51].

Dogs with severe mitral regurgitation have poor prognosis even with all the pharmacological options that currently exist [53]. Recent improvements in cardiopulmonary bypass techniques have enabled its use in small breed dogs. In the case of prosthetic valves, matching the size of the valve and conquering thrombosis is essential for long-term prognosis. Recently, successful techniques for mitral valve repair with annuloplasty and chordal replacement have been utilized, which enables long-term survival for severe myxomatous mitral valve disease patients. Costs and availability are the major drawbacks of this option [54-57].

CONCLUSION

The aging process results in a host of physiological and
biological changes that lead to progressive HF. Nearly any CVD can lead to HF. HF in geriatric dogs is considered to be the result of structural and functional cardiac disorders that impair ventricular filling and ejection, and is broadly classified into: Diastolic heart failure is defined as HF with preserved ejection fraction (HF/PEF), systolic heart failure is also known as HF with low ejection fraction (HF/Low-EF). Importantly, HF/PEF accounts for approximately 50% of all HF patients and its prevalence is higher in the elderly.

In humans, mortality and morbidity benefits for HF/Low-EF have been reported with angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), β-blockers and aldosterone antagonists, and the hydralazine-nitrate combination in patients intolerant to ACE inhibitors or nitrates. Therapies for symptom control and morbidity benefit include diuretics and digoxin. The most common and suggested therapy for dogs with HF by ACVIM panelists is furosemide, ACE-I, pimobendan. Pharmacological therapy is limited as the results of small trials have been inconclusive. To date, clinical trials in HF/PEF patients have not shown mortality benefit so that management is focused on symptom relief and treatment of the underlying cause.

REFERENCES
